Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term Safety and Efficacy of HRS-5965 in Primary IgA Nephropathy
NCT07582133Phase 2Recruiting
- Sponsor
- Chengdu Suncadia Pharmaceuticals
- Start
- Jul 2026
- Primary completion
- Jul 2029
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of HRS-5965 in IgA nephropathy (IgAN), sponsored by Chengdu Suncadia Pharmaceuticals. Started Jul 2026; status: recruiting.
02
Drugs
HRS-5965
03
Conditions
IgA nephropathy (IgAN)
Beyond the preview
Go deeper on NCT07582133.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07582133.